Acquired estrogen independence and antiestrogen resistance in breast cancer: Estrogen receptor driven phenotypes?

Trends in Endocrinology and Metabolism

Volumn 7, Issue 8, 1996, Pages 291-301

  Clarke, Robert ^a   Brünner, Nils ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CELL PROLIFERATION; ESTROGEN METABOLISM; FEMALE; HORMONE RECEPTOR INTERACTION; HORMONE RESISTANCE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; SECOND MESSENGER; TRANSCRIPTION REGULATION;

EID: 0030272097     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(96)00127-0     Document Type: Short Survey

References (49)

1. Ali S, Metzger D, Bornert J-M, Chambon P: 1993. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 12:1153-1160.
2. Aronica SM, Katzenellenbogen BS: 1993. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7:743-752.
3. Baniahmad C, Nawaz Z, Baniahmad A, et al.: 1995. Enhancement of estrogen receptor activity by SPT6: a potential coactivator. Mol Endocrinol 9:34-43.
4. Bates SE, Davidson NE, Valverius EM, et al.: 1988. Expression of transforming growth factor-α and its mRNA in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543-545.
5. Berry M, Metzger D, Chambon M: 1990. Role of the two activating domains of the estrogen receptor in the cell-type and promoter-context dependent agonistic activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818.
6. Briehl MM, Flomerfelt FA, Wu X-P, Miesfeld RL: 1990. Transcriptional analyses of steroid regulated gene networks. Mol Endocrinol 4:287-294.
7. Brunner N, Boulay V, Fojo A, et al.: 1993a. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53:283-290.
8. Brunner N, Frandsen TL, Holst-Hansen C, et al.: 1993b. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53:3229-3232.
9. Catherine WH, Wolf DM, Jordan VC: 1995. A naturally occurring estrogen receptor point mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 9:1053-1063.
10. Cavailles V, L'Horset F, Lopez G, et al.: 1995. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J 14:3741-3751.
11. Clarke R, Lippman ME: 1992. Antiestrogens resistance: mechanisms and reversal. In: Teicher BA, ed. Drug Resistance in Oncology. New York, Marcel Dekker, pp 501-536.
12. Clarke R, Dickson RB, Lippman ME: 1992. Hormonal aspects of breast cancer: growth factors, drugs, and stromal interactions. Crit Rev Oncol Hematol 12:1-23.
13. Clarke R, Brünner N, Katzenellenbogen BS, et al.: 1989. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc Natl Acad Sci USA 86:3649-3653.
14. Clarke R, Skaar T, Baumann K, et al.: 1994. Hormonal carcinogenesis in breast cancer cellular and molecular studies of malignant progression. Breast Cancer Res Treat 31:237-248.
15. Clarke R, Skaar T, Leonessa F, et al.: 1996. The acquisition of an antiestrogen resistant phenotype in breast cancer: the role of cellular and molecular mechanisms. In: Hait W, ed. Cancer Treatment and Research: Drug Resistance. Norwell, Kluwer, pp 263-283.
16. Curtis SW, Korach KS: 1991. Uterine estrogen receptor-DNA complexes: effects of different ERE sequences, ligands, and receptor forms. Mol Endocrinol 5:959-966.
17. Danielian PS, White R, Lees JA, Parker MG: 1992. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:1025-1033.
18. Dauvois S, Danielian PS, White R, Parker MG: 1992. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037-4041.
19. Encarnacion CA, Ciocca DR, McGuire WL, et al.: 1993. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-246.
20. Fawell SE, White R, Hoare S, et al.: 1990. Inhibition of estrogen receptor-DNA binding by the "pure antiestrogen" ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883-6887.
21. Forman BM, Yang C-R, Stanley F, Casanova J, Samuels HH: 1988. C-erbA protooncogenes mediate thyroid hormone-dependent and -independent regulation of the rat growth hormone and prolactin genes. Mol Endocrinol 2:902-911.
22. Gilles C, Thompson EW: 1996. The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J 2:1-15.
23. Gottardis MM, Jordan VC: 1988. Development of tamoxifen-stimulated growth of MCF-7 tumors in athyrnic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187.
24. Halachmi S, Marden E, Martin G, et al.: 1994. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455-1458.
25. Helmer EB, Raaka BM, Samuels HH: 1996. Hormone-dependent and -independent transcriptional activation by thyroid hormone receptors are mediated by different mechanisms. Endocrinology 137:390-399.
26. Inano K, Curtis SW, Korach KS, Omata S, Horigome T: 1994. Heat shock protein 90 strongly stimulates the binding of purified estrogen receptor to its responsive element. J Biochem 116:759-766.
27. Joel PB, Traish AM, Lannigan DA: 1995. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol 9:1041-1052.
28. Johnson MD, Westley BR, May FEB: 1989. Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 59:727-738.
29. Johnston SRD, Saccanti-Jotti G, Smith IE, Newby J, Dowsett M: 1995. Change in oestrogen receptor expression and function in tamoxifen-resistant breast cancer. Endocr Rel Cancer 2:105-110.
30. Kato S, Endoh H, Masuhiro Y, et al.: 1995. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494.
31. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: 1987. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355-4360.
32. Klinge CM, Peale FV, Hilf R, Bambara RA, Zain S: 1992. Cooperative estrogen receptor interaction with consensus or variant estrogen response elements in vitro. Cancer Res 52: 1073-1081.
33. Knabbe C, Lippman ME, Wakefield LM, et al.: 1987. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428.
34. Kyprianou N, English HF, Davidson NE, Isaacs JT: 1991. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162-166.
35. Landel CC, Kushner PJ, Greene GL: 1994. The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol 8:1407-1419.
36. Martinez E, Dusserre Y, Wahli W, Mermod N: 1991. Synergistic transcriptional activation by CTF/NF-I and the estrogen receptor involves stabilized interactions with a limiting target factor. Mol Cell Biol 11:2937-2945.
37. Masamura S, Santner SJ, Heitjan DF, Santen RJ: 1995. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80:2918-2925.
38. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW: 1995. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669.
39. Migliaccio A, Di Domenico M, Green S, et al.: 1989. Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding. Mol Endocrinol 3:1061-1069.
40. Norris J, Fan D, Aleman C, et al.: 1995. Identification of a new subclass of Alu DNA repeats, which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem 270:22,777-22,782.
41. Onate SA, Tsai SY, Tsai M-J, O'Malley BW: 1995. Seqence and characterization of a coactivator for the steroid hormone receptor super-family. Science 270:1354-1371.
42. Singh L, Wilson AJ, Baum M, et al.: 1988. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO (Nolvadex) trial. Br J Cancer 57:612-614.
43. Tora L, White J, Brou C, et al.: 1989. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487.
44. Tzukerman M, Zhang X-K, Hermann T, et al.: 1990. The human estrogen receptor has transcriptional activitor and repressor functions in the absence of ligand. New Biologist 2:613-620.
45. Webster NJG, Green S, Jin JR, Chambon P: 1988. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54:199-207.
46. Worland PJ, Bronzert D, Dickson RB, et al.: 1989. Secreted and cellular polypeptide patterns of MCF-7 human breast cancer cells following either estrogen stimulation or v-H-ras transfection. Cancer Res 49:51-57.
47. Yarden RI, Lauber AH, El-Ashry D, Chrysogelos SA: 1996. Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology 137:2739-2747.
48. Yoshinaga SK, Peterson CL, Herskowitz I, Yamamoto KR: 1992. Roles of SWI1, SWI2, and SWI3 proteins for transcriptional enhancement by steroid receptors. Science 258: 1596-1604.
49. Zhuang Y, Katzenellenbogen BS, Shapiro DJ: 1995. Estrogen receptor mutants which do not bind 17β-estradiol dimerize and bind to the estrogen response element in vivo. Mol Endocrinol 9:457-466.